Rose McNulty

During the upcoming Community Oncology Alliance (COA) Payer Exchange Summit, a panel discussion on applying value-based insurance design (VBID) in oncology will explore ways in which the coronavirus disease 2019 crisis can be an opportunity for growth.

Researchers analyzed 2 randomized studies to learn how adding radiation therapy to pembrolizumab immunotherapy affects non-small cell lung cancer patient outcomes.

Experts in cancer care and payment discussed the future of oncology care in a panel discussion hosted by Avalere Health on October 21, 2020.

Cancer screenings and treatments saw a sharp decline during the early months of the pandemic. The authors of a new study on the delays in care warn that the fallout may be grim.

A new analysis predicts close to 3000 additional deaths over a 10-year period in patients who faced delays in breast cancer treatment during the pandemic.

Two abstracts presented at the Migraine Trust Virtual Symposium investigated lasmiditan’s safety in elderly and pediatric migraine patients.

A study and accompanying editorial from the Journal of Clinical Oncology found that Hodgkin lymphoma survivors still face a higher risk of non-cancer death than the general population.

Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis.

Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.

Research from the American Cancer Society suggests that more young people are being introduced to nicotine via e-cigarettes.